1. Thio-ProTide strategy: A novel H2S donor–drug conjugate (DDC) alleviates hepatic injury via innate lysosomal targeting.
- Author
-
Jin, Haowen, Ma, Jie, Xu, Bixin, Xu, Sitao, Hu, Tianyu, Jin, Xin, Wang, Jiankun, Wang, Guangji, and Zhen, Le
- Subjects
DRUG discovery ,HEPATIC fibrosis ,HYDROGEN sulfide ,THERAPEUTICS ,LIVER injuries - Abstract
Hydrogen sulfide (H 2 S) is a gas signaling molecule with versatile bioactivities; however, its exploitation for disease treatment appears challenging. This study describes the design and characterization of a novel type of H 2 S donor–drug conjugate (DDC) based on the thio-ProTide scaffold, an evolution of the ProTide strategy successfully used in drug discovery. The new H 2 S DDCs achieved hepatic co-delivery of H 2 S and an anti-fibrotic drug candidate named hydronidone, which synergistically attenuated liver injury and resulted in more sufficient intracellular drug exposure. The potent hepatoprotective effects were also attributed to the H 2 S-mediated multipronged intervention in lipid peroxidation both at the whole cellular and lysosomal levels. Lysosomal H 2 S accumulation and H 2 S DDC activation were facilitated by the hydrolysis through the specific lysosomal hydrolase, representing a distinct mechanism for lysosomal targeting independent of the classical basic moieties. These findings provided a novel pattern for the design of optimally therapeutic H 2 S DDC and organelle-targeting functional molecules. The thio-ProTides, as novel H 2 S donor–drug conjugates, enabled the co-delivery of H 2 S with pharmacologically active molecules. Their lysosomal H 2 S accumulation potentially enhanced the mitigation of hepatic lipotoxicity and fibrosis. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF